Expertise in
7
conditions

Dr. Sanford M. Wolfe

Rheumatology
Mvhe Inc
2451 Wayne Ave, 
Dayton, OH 
Accepting New Patients
46 Years of Experience
Expertise in
7
conditions
Mvhe Inc
2451 Wayne Ave, 
Dayton, OH 

Overview

Sanford Wolfe is a Rheumatologist in Dayton, Ohio. Dr. Wolfe has been practicing medicine for over 46 years is highly rated in 7 conditions, according to our data. His top areas of expertise are Rheumatoid Arthritis (RA), Osteoporosis, Postmenopausal Osteoporosis, and Melorheostosis with Osteopoikilosis. Dr. Wolfe is currently accepting new patients.

His clinical research consists of participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Rheumatology

Licenses

Internal Medicine in OH

Hospital Affiliations

Upper Valley Medical Center
Miami Valley Hospital
Kettering Health Dayton
Mercer County Joint Township Community Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 21 Less Insurance Carriers -

Locations

MVHE INC
2451 Wayne Ave, Dayton, OH 45420
Other Locations
MVHE INC
2400 Lakeview Dr, Suite 100, Beavercreek, OH 45431

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Completed
Publish Date: February 18, 2025
Intervention Type: Drug
Study Drugs: Rituximab, Standard therapy (Including Immunosuppressants), Standard therapy (Excluding Immunosuppressants), Steroid Taper
Study Phase: Phase 3
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Enrollment Status: Completed
Publish Date: March 27, 2024
Intervention Type: Biological, Drug
Study Drugs: GSK3196165, Tofacitinib, Methotrexate, Folic acid
Study Phase: Phase 3
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
Enrollment Status: Terminated
Publish Date: February 07, 2024
Intervention Type: Drug, Biological
Study Drugs: Otilimab, csDMARD
Study Phase: Phase 3
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Olokizumab
Study Phase: Phase 3
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
Enrollment Status: Completed
Publish Date: July 17, 2023
Intervention Type: Drug, Biological
Study Drugs: GSK3196165, Sarilumab, csDMARDs
Study Phase: Phase 3
View 6 Less Clinical Trials
Similar Doctors
Expertise in
20
conditions
Dr. Shobha Wani
Rheumatology
Expertise in
20
conditions
Dr. Shobha Wani
Rheumatology

Office

3075 Governors Place Blvd Ste 110, 
Dayton, OH 
 (3.2 miles away)
937-296-0015
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shobha Wani is a Rheumatologist in Dayton, Ohio. Dr. Wani is highly rated in 20 conditions, according to our data. Her top areas of expertise are Sjogren Syndrome, Rheumatoid Arthritis (RA), Psoriatic Arthritis, and Musculocontractural Ehlers-Danlos Syndrome (mcEDS).

Expertise in
6
conditions
Dr. John Harley
Rheumatology
Expertise in
6
conditions
Dr. John Harley
Rheumatology

Cincinnati Veterans Affairs Medical Center

3200 Vine St, 
Cincinnati, OH 
 (45.4 miles away)
513-861-3100
Languages Spoken:
English
See accepted insurances

John Harley is a Rheumatologist in Cincinnati, Ohio. Dr. Harley is highly rated in 6 conditions, according to our data. His top areas of expertise are Systemic Lupus Erythematosus (SLE), Sjogren Syndrome, Arthritis, Lupus Nephritis, and Thymectomy.

Expertise in
18
conditions
Dr. Gregory J. Delorenzo
Rheumatology
Expertise in
18
conditions
Dr. Gregory J. Delorenzo
Rheumatology

Trihealth H LLC

7825 Laurel Ave, 
Cincinnati, OH 
 (39.4 miles away)
513-561-4811
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gregory Delorenzo is a Rheumatologist in Cincinnati, Ohio. Dr. Delorenzo is highly rated in 18 conditions, according to our data. His top areas of expertise are Rheumatoid Arthritis (RA), Psoriatic Arthritis, Psoriasis, and Postmenopausal Osteoporosis. Dr. Delorenzo is currently accepting new patients.

Frequently Asked Questions about Dr. Sanford M. Wolfe

How do I make an appointment with Dr. Sanford M. Wolfe?

You can book an appointment with Dr. Sanford M. Wolfe by calling their office at 937-252-1831. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sanford M. Wolfe a top-rated expert for Rheumatoid Arthritis (RA)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sanford M. Wolfe is classified as an Distinguished expert for Rheumatoid Arthritis (RA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sanford M. Wolfe specialize in?

While Dr. Sanford M. Wolfe is a Rheumatology, they have specific expertise in Rheumatoid Arthritis (RA), Osteoporosis, and Postmenopausal Osteoporosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Rheumatology.

Does Dr. Sanford M. Wolfe accept my insurance?

Dr. Sanford M. Wolfe accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 937-252-1831 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wolfe's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile